Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05865470
Other study ID # 22-001292
Secondary ID R01DA057252
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date September 1, 2024
Est. completion date August 1, 2028

Study information

Verified date May 2024
Source University of California, Los Angeles
Contact Ziva D Cooper, PhD
Phone 310-983-3417
Email zcooper@mednet.ucla.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the age-dependent effects of smoked and oral THC on abuse liability, intoxication, analgesia and impairment as a function of age.


Description:

The overall objective of this placebo-controlled, outpatient study is to compare the dose-dependent effects of smoked and oral THC on analgesia and endpoints directly related to adverse consequences of use including abuse liability, intoxication, and impairment as a function of age and sex.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 103
Est. completion date August 1, 2028
Est. primary completion date August 1, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male or non-pregnant female aged 18-65 years according to the below criteria: EMERGING ADULTS: 18-25 years of age (+/- one year) MIDDLE-AGED ADULTS: 35-45 years of age (+/- one year) LATE MIDDLE-AGED ADULTS: 55-65 years of age (+/- one year) - Report weekly-monthly use of cannabis (with primary mode of use via inhalation) over the past 6 months prior to screening - Not currently seeking treatment for their cannabis use - No reported clinically significant adverse effects with cannabis use - Have a Body Mass Index from 18.5 - 34kg/m2 - Able to perform all study procedures - FEMALES: Currently practicing an effective form of birth control if pre-menopausal Exclusion Criteria: - Meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) criteria for any substance use disorder other than nicotine and mild cannabis use disorder - Report using other illicit drugs in the prior 4 weeks - Evidence of severe psychiatric illness (e.g. mood disorder with functional impairment or suicide risk, schizophrenia) or medical condition (i.e., hypertension) judged by the study physician (and PI to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent. - Current predominant licit use of medical cannabis - Current use of prescription or regular use of over the counter medications (with the exception of hormonal contraceptives and hormone replacement therapy). Current use of herbal supplements that may affect study outcomes or interact with study drug (i.e., St Johns wort, kava, L-tryptophan, melatonin) - If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures - Current pain - Pregnancy is exclusionary due to the possible effects of the study medication on fetal development - History of an allergic reaction or adverse reaction to cannabis is exclusionary. - Currently enrolled in another research protocol - Not using a contraceptive method (hormonal or barrier methods) - The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary. - Intolerance to lactose and sesame (ingredients in the oral THC preparation) - Insensitivity to the Cold Pressor Test

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cannabis
smoked cannabis
Dronabinol
Oral delta-9-THC
Smoked Placebo
Placebo Cannabis
Oral Placebo
Oral Placebo

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of California, Los Angeles National Institute on Drug Abuse (NIDA)

Outcome

Type Measure Description Time frame Safety issue
Primary Subject-rated drug effects Average and peak subjective ratings of drug effects associated with abuse liability and intoxication as measured using visual analogue scales (VAS; 1-100mm). 6 hours
Primary Analgesia as measured using the Cold Pressor Test Peak and average pain threshold and tolerance assessed using the Cold Pressor Test 6 hours
Primary Impairment The primary outcome measure for performance will be the peak difference from baseline scores of the Global Impairment Score 6 hours
Primary Pharmacokinetics of THC and metabolites Plasma levels of THC, 11-OH-THC, and THCCOOH 6 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care